153 related articles for article (PubMed ID: 27699663)
1. Impact of point mutation P29S in RAC1 on tumorigenesis.
Rajendran V; Gopalakrishnan C; Purohit R
Tumour Biol; 2016 Nov; 37(11):15293-15304. PubMed ID: 27699663
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamic simulation reveals damaging impact of RAC1 F28L mutation in the switch I region.
Kumar A; Rajendran V; Sethumadhavan R; Purohit R
PLoS One; 2013; 8(10):e77453. PubMed ID: 24146998
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Differences of Activation of Rac1
Senyuz S; Jang H; Nussinov R; Keskin O; Gursoy A
J Phys Chem B; 2021 Apr; 125(15):3790-3802. PubMed ID: 33848152
[TBL] [Abstract][Full Text] [Related]
4. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
5. RAC1P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
[TBL] [Abstract][Full Text] [Related]
6. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
7. [Recurrent somatic activating RAC1 mutations in melanoma].
Dereure O
Ann Dermatol Venereol; 2012 Nov; 139(11):785-6. PubMed ID: 23199784
[No Abstract] [Full Text] [Related]
8. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
9. Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR.
Toyama Y; Kontani K; Katada T; Shimada I
Sci Adv; 2019 Mar; 5(3):eaav8945. PubMed ID: 30891502
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
11. RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
[TBL] [Abstract][Full Text] [Related]
12. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract][Full Text] [Related]
13. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
[TBL] [Abstract][Full Text] [Related]
14. Decreased conformational stability in the oncogenic N92I mutant of Ras-related C3 botulinum toxin substrate 1.
Toyama Y; Kontani K; Katada T; Shimada I
Sci Adv; 2019 Aug; 5(8):eaax1595. PubMed ID: 31457101
[TBL] [Abstract][Full Text] [Related]
15. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
16. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
17. The use of surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET) to monitor the interaction of the plant G-proteins Ms-Rac1 and Ms-Rac4 with GTP.
Brecht M; Sewald K; Schiene K; Keen G; Fricke M; Sauer M; Niehaus K
J Biotechnol; 2004 Aug; 112(1-2):151-64. PubMed ID: 15288950
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Dendritic Actin Network Formation in Extended Lamellipodia Drives Proliferation in Growth-Challenged Rac1
Mohan AS; Dean KM; Isogai T; Kasitinon SY; Murali VS; Roudot P; Groisman A; Reed DK; Welf ES; Han SJ; Noh J; Danuser G
Dev Cell; 2019 May; 49(3):444-460.e9. PubMed ID: 31063759
[TBL] [Abstract][Full Text] [Related]
19. RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC; Uribe-Alvarez C; Chernoff J
Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
[TBL] [Abstract][Full Text] [Related]
20. Unique vulnerability of
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
bioRxiv; 2023 Jun; ():. PubMed ID: 37425776
[No Abstract] [Full Text] [Related]
[Next] [New Search]